In 40 seconds
Behavioural and psychological symptoms of dementia (BPSD) — agitation, aggression, apathy, depression, psychosis, wandering — affect the majority of people with dementia at some point. The 2023 systematic review of rTMS for BPSD found a positive direction-of-effect signal for reducing agitation, apathy and depression. Wu 2015 (n=54) showed DLPFC rTMS reduced BEHAVE-AD scores at 6 weeks with persistence to 3 months. The evidence is preliminary, not confirmatory. Consumer low-intensity PEMF has no completed RCT specifically for BPSD. NICE recommends a structured non-pharmacological-first approach: identify and treat reversible causes (pain, infection, constipation, hunger, sensory deprivation, environmental triggers), then consider time-limited psychotropic medication only where non-pharm strategies have failed and symptoms are severe.
Quick facts
- BPSD prevalence: Affects the majority of people with dementia at some point
- rTMS for BPSD signal: 2023 systematic review — positive direction-of-effect, preliminary
- Wu 2015 trial: n=54 moderate AD — reduced BEHAVE-AD scores with DLPFC rTMS
- PEMF RCT for BPSD: None completed
- First-line approach: Identify and treat reversible causes — pain, infection, constipation, sensory issues
- Antipsychotics: Time-limited, lowest effective dose, only after non-pharm — risperidone is the only one licensed for short-term aggression in AD
- Avoid in DLB: Severe neuroleptic sensitivity — most antipsychotics contraindicated
What the evidence on agitation actually says
Agitation in dementia is not a single thing. It covers verbal aggression, physical aggression, restlessness, repetitive vocalisation, resistance to care, and wandering. The treatment response and the published trial evidence differ by sub-type.
Reversible causes first
The single highest-yield intervention is a structured search for reversible causes. In published audit cycles roughly 30–50% of new agitation in care-home dementia patients has a treatable medical cause: urinary tract infection, constipation, pain, dehydration, medication side effect, sensory deprivation (missing glasses or hearing aids), or environmental triggers. Address these before any neuromodulation or psychotropic decision.
Non-pharmacological strategies with evidence
Cognitive stimulation therapy (CST) — NICE-endorsed in NG97 — reduces agitation in some patients. Person-centred care planning, structured activity, music, and reminiscence have small-to-moderate published effects. Environmental modification (lighting, noise reduction, clear signage) reduces wandering and confusion-driven agitation.
rTMS evidence
The 2023 systematic review of TMS for BPSD pooled small trials and found a positive direction-of-effect signal across apathy, depression and agitation outcomes. Wu et al. 2015 (n=54, moderate AD, DLPFC at 20 Hz, 4 weeks) showed BEHAVE-AD reduction at 6 weeks with persistence to 3 months. This is consistent with the broader rTMS-in-depression literature where the same protocol has well-established efficacy. The evidence is preliminary in dementia BPSD but the direction is positive and the safety profile in the published trials has been acceptable. NICE NG97 still recommends against rTMS for dementia outside a clinical trial.
PEMF evidence
Consumer low-intensity PEMF has no completed RCT specifically for dementia BPSD. The general anxiolytic and sleep-quality evidence base for PEMF in non-dementia adults is small and inconsistent. Do not extrapolate.
Antipsychotics
Antipsychotics carry a documented increase in stroke and mortality risk in dementia. They should be used time-limited (typically 12 weeks), at the lowest effective dose, only after non-pharmacological strategies, and only for severe symptoms with risk of harm. Risperidone is the only antipsychotic licensed in the UK for short-term treatment of persistent aggression in AD. In Lewy body dementia, severe neuroleptic sensitivity makes most antipsychotics contraindicated; quetiapine at low dose is the cautious choice if any is required.
What this means for a UK family
For a relative with new or worsening agitation, the structured approach is: GP review with infection/pain/constipation screen and polypharmacy review; memory clinic involvement; non-pharmacological strategies (CST, environmental modification, structured activity); time-limited risperidone or analogous only where non-pharm has failed and risk is high. rTMS sits as a research-trial option for refractory cases at major centres. Consumer PEMF is not on the evidence-based first-line list — frame it as wellness for the carer.
Frequently asked questions
Will rTMS reduce my husband's agitation?
There is preliminary positive trial evidence (Wu 2015; 2023 BPSD systematic review). It is not confirmed at phase-3 RCT level. NICE NG97 still recommends rTMS for dementia only inside a clinical trial. Ask the memory clinic about trial availability.
Is risperidone safe in dementia agitation?
Risperidone is the only antipsychotic licensed in the UK for short-term treatment of persistent aggression in AD, time-limited (typically 12 weeks), at the lowest effective dose. It carries documented increased stroke and mortality risk and should be reviewed regularly. In Lewy body dementia it is contraindicated.
What about home PEMF for agitation?
There is no completed RCT for low-intensity consumer PEMF in dementia BPSD. The general anxiolytic evidence in non-dementia adults is small and inconsistent.
Why does my dad always get worse in the afternoon?
Late-afternoon worsening is sundowning. See our /dementia-sundowning page for the specific evidence and first-line strategies (bright light therapy, structured activity, sleep hygiene).
Could pain be driving the agitation?
Yes — untreated pain is a common but under-recognised driver of agitation in people who cannot articulate it. Structured pain assessment (Abbey Pain Scale or DOLOPLUS) and a trial of regular paracetamol can sometimes dramatically reduce agitation.
Could a UTI be causing it?
Yes — UTI is one of the commonest reversible causes of acute agitation and confusion in older adults. A urine dip and culture is high-yield in any acute behavioural change.
Should we use a PRN sedative?
Avoid PRN benzodiazepines or sedatives as a routine response — they increase falls, paradoxical agitation and confusion, and can mask reversible causes. Reserve for true emergencies and review.
Where does cognitive stimulation therapy sit?
CST is the only non-pharmacological intervention NICE NG97 specifically endorses for cognition and wellbeing in mild-to-moderate dementia. It is available on the NHS through some memory clinics. Worth asking for before pharmacological steps.
Related dementia pages on PEMF UK
Looking for a PEMF clinic in the UK?
We list every credible PEMF therapy provider in the UK. Please remember: no UK clinic can legally claim to treat dementia with PEMF or rTMS.